GNS Genus plc

28.00USD2126.00 GBp · LSE-1.39%Mkt Cap: 1.80B USDP/E: 5.00

Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Gen…

Institutional holders10 on file

Key Statistics

Company
Market Cap1.80B USD
Enterprise Value1.96B USD
Revenue (TTM)866.62M USD
Gross Profit322.36M USD
Net Income (TTM)375.70M USD
Revenue/Share13.11 USD
Last Price28.00 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees2.9K
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB0002074580
Valuation
P/E (Trailing)5.00
P/E (Forward)18.26
PEG—
EV/EBITDA14.51
EV/Revenue2.26
P/S2.08
P/B1.83
EPS (TTM)5.60 USD
EPS (Forward)1.56 USD
52W Range
25.5914% of range42.40
52W High42.40 USD
52W Low25.59 USD
Profitability
Gross Margin37.20%
Oper. Margin12.00%
EBITDA Margin15.59%
Profit Margin43.35%
ROE37.21%
ROA28.02%
ROIC10.05%
ROCE10.08%
Growth
Revenue Growth-4.10%
Earnings Growth1341.70%
Cash Flow & Leverage
Operating CF97.97M USD
CapEx (TTM)23.83M USD
FCF Margin7.89%
FCF Yield3.80%
Net Debt84.01M USD
Net Debt/EBITDA0.62
Net Debt/FCF1.23
Balance Sheet
Debt/Equity0.14
Current Ratio2.21
Quick Ratio1.42
Book Value/Sh15.27 USD
Cash/Share0.87 USD
Dividends
Fwd Div Rate0.0046 USD
Trail. Div Rate0.0046 USD
Div. Yield1.63%
5Y Avg Yield1.32%
Payout Ratio7.74%
Ex-Div DateNov 12, 2026
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.24 USD
Upside (mean)+40.2%
Target Range30.95 USD – 48.72 USD
30.95+40.2% to mean48.72
# Analysts13
Ownership
Shares Out.64.31M
Float61.64M
Insiders0.77%
Institutions69.33%
Technical
SMA 5029.54 (-5.2%)
SMA 20031.29 (-10.5%)
Beta0.86
S&P 52W Chg12.08%
Avg Vol (30d)198.91K
Avg Vol (10d)141.29K
Technical Indicators
RSI (14)35.7
MACD-13.4831
MACD Signal16.5381
MACD Hist.-30.0212
BB Upper32.62 USD
BB Middle30.56 USD
BB Lower28.51 USD
BB Width13.45%
ATR (14)1.094 USD
Vol Ratio (20d)2.22x

About Genus (LON: GNS)

›

Genus (LON: GNS) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 2,921 employees.

The shares were at 2126.00 GBp on 19 November 2026, down 10.9% over 52 weeks. Its 52-week range is 1943.00 GBp to 3220.00 GBp: the price is 34.0% below the high and 9.4% above the low.

At a market capitalisation of 1.37B GBP, it trades at 5.0 times trailing earnings and 18.3 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 85% for GNS. It pays a dividend yielding 1.63% (it pays out 8% of its earnings), against a median of 0.94% among the dividend payers in that peer group.

Genus reports return on equity of 37.2%, an operating margin of 12.0% and revenue down 4.1% year over year.

Its debt exceeds its cash by 63.80M GBP, a debt-to-equity ratio of 0.14. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Buy; their mean price target of 2980.00 GBp is 40.2% above the current price. The next earnings report is expected on 25 February 2027.